

Supplement Table S3.**Serum biomarker levels at baseline comparing JIA patients with inactive/active disease and remission off medication/non-achievement of remission at 18-year FU.**

	Baseline biomarkers	Baseline biomarkers:	Baseline biomarkers	Baseline biomarkers		Baseline biomarkers	Baseline biomarkers	
	all	clinical examination at 18-year FU	Inactive disease at 18-year FU	Active disease at 18-year FU	p-value	Remission off medication at 18-year FU	Not in remission at 18-year FU	p-value
N	236	199*	112*	81		76**	117	
IL-1b	16.5 (6.7-30.5)	16.5 (6.3-30.7)	13.8 (6.2-27.6)	21.7 (8.9-66)	0.020	11.7 (1.9-25.9)	21.3 (8.9-56)	0.015
IL-4	88.6 (55.4-132.7)	82.6 (54.0-124.8)	80.9 (51-126)	88.4 (60-123)	0.244	80.9 (50.0-125)	88.3 (56.4-126)	0.455
IL-6	6.7 (3.2-13.0)	6.2 (3.2-12.3)	5.1 (2.7-10.3)	8.1 (4.1-15.5)	0.011	5.3 (2.7-10.3)	7.0 (3.2-14.2)	0.093
IL-10	5.3 (2.3-7.1)	5.0 (1.6-6.8)	4.7 (2.2-6.7)	5.4 (1.5-7.2)	0.325	4.4 (1.2-6.4)	5.4 (2.7-7.2)	0.142
IL-12	13.4 (0.5-72.5)	28.4 (0.5-75.4)	11.8 (0.5-65.5)	53.8 (0.8-92.8)	0.002	1.1 (0.5-71.0)	34 (0.5-84.7)	0.034
IL-13	497 (387-621)	497 (387-621)	469 (385-579)	534 (424-693)	0.010	461 (385-574)	509 (420-658)	0.029
IL-17	10.3 (0.8-16.2)	8.0 (0.8-15.2)	7.3 (0.8-16.0)	10.3 (1.9-15.2)	0.278	6.9 (0.7-15.8)	8.0 (1.9-15.6)	0.242
IL-18	205 (136-291)	190 (131-275)	183 (129-241)	206 (133-296)	0.333	185 (122-239)	199 (135-292)	0.321
TNFα	9.2 (1.7-16.6)	7.3 (1.0-14.6)	5.9 (1.0-15.0)	8.9 (3.3-14.6)	0.144	5.5 (1.0-14.9)	8.4 (2.7-14.8)	0.094
MMP-3	5174 (1747-17493)	5245 (1775-16407)	2996 (1659-12868)	8452 (3230-25920)	<0.001	2742 (1334-17274)	7011 (2193-16442)	0.020
CCL-2	180 (112-251)	171 (111-250)	163 (108-255)	185 (117-243)	0.615	153 (103-236)	184 (115-256)	0.265
CD25	587 (420-766)	550 (414-738)	538 (421-720)	572 (386-760)	0.817	520 (423-717)	569 (403-755)	0.181
GM-CSF	0.4 (0.4-3.8)	0.4 (0.4-4.5)	0.4 (0.4-3.7)	0.53 (0.4-5.6)	0.044	0.4 (0.4-3.8)	0.53 (0.4-4.6)	0.662
MPO	2294 (1579-3572)	2291 (1522-3412)	2322 (1526-3244)	2341 (1528-3860)	0.370	2370 (1651-3135)	2267 (1500-3958)	0.688
S100A9	511 (314-1277)	511 (300-1151)	448 (285-1254)	652 (404-1215)	0.024	450 (300-1383)	643 (312-1159)	0.181
S100A1	924 (434-1610)	904 (424-1632)	809 (327-1599)	1355 (651-1917)	0.002	837 (309-1609)	1228 (523-1649)	0.074

Values are in picograms (pg)/ milliliter (ml) expressed as median (interquartile range (IQR)). P-values are calculated using Mann-Whitney U test.

*: 199 patients were eligible for clinical evaluation at 18-year FU. 112 patients had inactive disease according to Wallace provisional criteria (25) and 81 had active disease. Missing values regarding the criteria were seen in 6 patients.

** : 76 patients achieved remission off medication according to Wallace criteria (26) and 117 patients did not fulfill these criteria of remission. Missing values regarding the criteria were seen in 6 patients.

IL: interleukin, TNF α : tumor necrosis factor alpha; MMP-3: matrix metalloproteinase 3; CCL-2: chemokine ligand 2; GM-CSF: granulocyte-macrophage colony-stimulating factor; MPO: myeloperoxidase; S100A9/A12: S100 calcium-binding protein A9/A12.